A Multicenter, Open-label, Single-arm, Phase II Clinical Trial to Evaluate the Preventive Effect of Pegylated G-CSF (PG) on Neutropenia in Patients With Metastatic Triple-negative Breast Cancer (mTNBC) Receiving Sacituzumab Govitecan (SG)
Latest Information Update: 04 Nov 2024
At a glance
- Drugs Sacituzumab govitecan (Primary) ; Pegfilgrastim
- Indications Neutropenia; Triple negative breast cancer
- Focus Therapeutic Use
- 04 Oct 2024 New trial record